Criteria to Guide Evaluation and Testing of Patients Under Investigation for COVID-19 by unknown
 Criteria to Guide Evaluation and Testing of Patients Under Investigation for 
COVID-19 
Clinicians considering testing of persons with possible COVID-19 should continue 
to work with their local and state health departments to coordinate testing 
through public health laboratories, or use COVID-19 diagnostic testing, authorized 
by the Food and Drug Administration under an Emergency Use Authorization 
(EUA) through clinical laboratories.  Increasing testing capacity will allow clinicians 
to consider COVID-19 testing for a wider group of symptomatic patients. 
Clinicians should use their judgment to determine if a patient has signs and 
symptoms compatible with COVID-19 and whether the patient should be tested. 
Most patients with confirmed COVID-19 have developed fever1 and/or symptoms 
of acute respiratory illness (e.g., cough, difficulty breathing). Priorities for testing 
include: 
Other considerations that may guide testing are epidemiologic factors such as the 
occurrence of local community transmission of COVID-19 infections in a 
jurisdiction. Clinicians are strongly encouraged to test for other causes of 
respiratory illness. 
 
Priorities for testing patients with suspected COVID-19 infection 
 
 
Priorities for Laboratory Testing for COVID-19 
PRIORITY 1 
Ensure optimal care options for all hospitalized patients, lessen the risk of nosocomial infections, 
and maintain the integrity of the healthcare system 
Hospitalized patients 
Symptomatic healthcare workers 
PRIORITY 2 
Ensure that those who are at highest risk of complication of infection are rapidly identified and 
appropriately triaged 
Patients in long-term care facilities with symptoms 
Patients 65 years of age and older with symptoms 
Patients with underlying conditions with symptoms 
First responders with symptoms 
PRIORITY 3 
As resources allow, test individuals in the surrounding community of rapidly increasing hospital 
cases to decrease community spread, and ensure health of essential workers 
Critical infrastructure workers with symptoms 
Individuals who do not meet any of the above categories with symptoms 
Health care workers and first responders 
Individuals with mild symptoms in communities experiencing high COVID-19 hospitalizations 
NON-PRIORITY 
Individuals without symptoms 
Recommendations for Reporting, Testing, and Specimen Collection 
Clinicians should immediately implement recommended infection prevention and 
control practices if a patient is suspected of having COVID-19. They should also 
notify infection control personnel at their healthcare facility and their state or 
local health department if a patient is classified as a PUI for COVID-19. State 
health departments that have identified a PUI or a laboratory-confirmed case 
should complete a PUI and Case Report form through the processes identified on 
CDC’s Coronavirus Disease 2019 website. State and local health departments can 
contact CDC’s Emergency Operations Center (EOC) at 770-488-7100 for assistance 
with obtaining, storing, and shipping appropriate specimens to CDC for testing, 
including after hours or on weekends or holidays. 
For initial diagnostic testing for COVID-19, CDC recommends collecting and testing 
upper respiratory tract specimens (nasopharyngeal swab). CDC also recommends 
testing lower respiratory tract specimens, if available. For patients who develop a 
productive cough, sputum should be collected and tested for COVID-19. The 
induction of sputum is not recommended. For patients for whom it is clinically 
indicated (e.g., those receiving invasive mechanical ventilation), a lower 
respiratory tract aspirate or bronchoalveolar lavage sample should be collected 
and tested as a lower respiratory tract specimen. Specimens should be collected 
as soon as possible once a PUI is identified, regardless of the time of symptom 
onset. See Interim Guidelines for Collecting, Handling, and Testing Clinical 
Specimens from Patients Under Investigation (PUIs) for COVID-19 and Biosafety 
FAQs for handling and processing specimens from suspected cases and PUIs. 
Footnotes 
1. Fever may be subjective or confirmed 
2.For healthcare personnel, testing may be considered if there has been exposure 
to a person with suspected COVID-19 without laboratory confirmation. Because 
of their often extensive and close contact with vulnerable patients in healthcare 
settings, even mild signs and symptoms (e.g., sore throat) of COVID-19 should be 
evaluated among potentially exposed healthcare personnel. Additional 
information is available in CDC’s Interim U.S. Guidance for Risk Assessment and 
Public Health Management of Healthcare Personnel with Potential Exposure in a 
Healthcare Setting to Patients with Coronavirus Disease 2019 (COVID-19). 
3.Close contact is defined as— 
a) being within approximately 6 feet (2 meters) of a COVID-19 case for a 
prolonged period of time; close contact can occur while caring for, living with, 
visiting, or sharing a healthcare waiting area or room with a COVID-19 case 
– or – 
b) having direct contact with infectious secretions of a COVID-19 case (e.g., being 
coughed on) 
If such contact occurs while not wearing recommended personal protective 
equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, 
eye protection), criteria for PUI consideration are met. 
Additional information is available in CDC’s updated Interim Infection Prevention 
and Control Recommendations for Patients with Confirmed COVID-19 or Persons 
Under Investigation for COVID-19 in Healthcare Settings. 
Data to inform the definition of close contact are limited. Considerations when 
assessing close contact include the duration of exposure (e.g., longer exposure 
time likely increases exposure risk) and the clinical symptoms of the person with 
COVID-19 (e.g., coughing likely increases exposure risk as does exposure to a 
severely ill patient). Special consideration should be given to healthcare personnel 
exposed in healthcare settings as described in CDC’s Interim U.S. Guidance for 
Risk Assessment and Public Health Management of Healthcare Personnel with 
Potential Exposure in a Healthcare Setting to Patients with COVID-19. 
4.Documentation of laboratory-confirmation of COVID-19 may not be possible for 
travelers or persons caring for COVID-19 patients in other countries. 
5.Affected areas are defined as geographic regions where sustained community 
transmission has been identified. For a list of relevant affected areas, see 
CDC’s Coronavirus Disease 2019 Information for Travel. 
Additional Resources: 
State health department after-hours contact listexternal icon 
Directory of Local Health Departmentsexternal icon 
World Health Organization (WHO) Coronavirusexternal icon 
WHO guidance on clinical management of severe acute respiratory infection 
when COVID-19 is suspectedexternal icon 
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